RPRX:NSD-Royalty Pharma plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 51.85

Change

-0.10 (-0.19)%

Market Cap

USD 32.48B

Volume

4.22M

Average Target Price

USD 51.00 (-1.64%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.36 (+2.82%)

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

+15.96 (+3.08%)

USD55.27B 18.98 14.64
MRNA Moderna, Inc

-4.64 (-3.58%)

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+2.01 (+1.28%)

USD34.27B 36.37 33.83
SGEN Seagen Inc

+3.03 (+1.63%)

USD33.25B 70.15 70.76
BGNE BeiGene, Ltd

+11.68 (+3.39%)

USD31.01B N/A N/A
GMAB Genmab A/S

-0.07 (-0.16%)

USD28.77B 26.59 3.08
BNTX BioNTech SE

+3.11 (+3.06%)

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
INCY Incyte Corporation

+3.40 (+3.75%)

USD19.83B 47.64 35.20

ETFs Containing RPRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.03% 32% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.03% 32% F 51% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 21,281.44% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 21,281.44% 99% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain -7.13% 32% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.13% 32% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 52.55% 51% F 24% F
Risk Adjusted Return -13.57% 35% F 27% F
Market Capitalization 32.48B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.60 33% F 45% F
Price/Book Ratio 7.30 35% F 23% F
Price / Cash Flow Ratio 19.48 5% F 21% F
EV/EBITDA 11.90 28% F 64% D
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 22.47% 94% A 93% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 97.55% 17% F 24% F
Technical Ratios  
Short Ratio 4.22 40% F 33% F
Short Percent 4.63% 63% D 41% F
Beta 0.69 84% B 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.